Your SlideShare is downloading. ×
Ega survey to ms and efta countries michele uda ega
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Ega survey to ms and efta countries michele uda ega


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Survey on good practices and obstaclesto the uptake of the biosimilars marketin Member States and EFTA CountriesMedicamentos Biosimilares: Present y futuroMichele UdaMember of the EGA Board and Chair of the Transparency working group12th of February, Madrid
  • 2. Stakeholders ContactedAll EU MS and EFTA countries;Represented either by: Health authorities and/or Health insurers
  • 3. Responding Countries = 24
  • 4. Outstanding Countries = 5
  • 5. Question 1 – Does your country have specialprescribing rules for biologicals and/ or forbiosimilars?
  • 6. Question 2- In your country, do you havespecific clauses removing biologicals fromautomatic substitution?
  • 7. Question 3 - Does your agency communicateinformation on biosimilars via their websiteto the general public? If yes, what are therecommendations put forward?
  • 8. Question 4 - Does your country havemeasures in place targeting the uptake ofbiosimilars? When were these introduced?
  • 9. Question 5 - Obstacles Listed by Member StatesQuality, safety and efficacy General perception that biosimilar medicines are inferior to innovators; Biosimilars concept not fully accepted/ understood by doctors; Prescribers concerns regarding primarily safety and efficacity of biosimilars; Currently, doctors are reluctant to prescribe biosimilars due to hypothetic uncertainties in safety and effectiveness of biosimilars; Patients’ misperceptions regarding biosimilar medicines;
  • 10. Question 5 - Obstacles Listed by Member StatePrescription practices Reluctance by physicians to prescribe/ deliver biosimilar medicine; Reluctance by doctors to switch brands; There is a widespread belief that biosimilars are inferior to innovators and that they are not interchangeable;
  • 11. Question 5 - Obstacles Listed by Member StateLegislative Issues Lack of regulation;Lack of incentives Lack of incentives to prescribe/deliver biosimilar medicines; No incentives are provided to doctors to use biosimilars through the (hospitals) reimbursement scheme;
  • 12. Question 6 - Uptake Measures Listed by Member StatePrescription rules and Incentives Prescription target/ quota; Enhance the prescription of biosimilars in hospitals; Set-up procedures for usage and substitution; Introduce some incentives for doctors to increase prescription of biosimialrs in patients who are starting the treatment.
  • 13. Question 6 - Uptake Measures Listed by Member StateProcurement procedures (1/2) National and regional hospital tenders for biologicals including biosimilars; Bidding system every year for the status of preferred biological products (biological products grouped together with their biosimilars);
  • 14. Question 6 - Uptake Measures Listed by Member StateProcurement procedures (2/2) Transparent pricing of pharmaceuticals in hospitals; Introduction of a daily lump sum for pathologies treated with biologicals in out-patient care; Another model is "preferred drug" that one drug, the least expensive will be the normal choice; Introduce more price incentives;
  • 15. Question 6 - Uptake Measures Listed by Member StateInformation campaigns (1/2) Provide specific information about biosimilars targeted at the prescribers; Clear and unbiased information from an independent source on the "concept" of biosimilars, their approval process and their safety, will be central; Create awareness for biosimilars;
  • 16. Question 6 - Uptake Measures Listed by Member StateInformation campaigns (2/2) Improve the knowledge of healthcare professionals on biosimilars (e.g. organisation of conferences with all stakeholders); Patient targeted information on the same issues as for doctors is thought to have added benefits;
  • 17. Question 6 - Uptake Measures Listed by Member StateSubstitution (1/2) Clear statement from EMA on the safety of substitution; Clear decisions on automatic substitution- possible or not- is also of importance; Automatic substitution will be reconsidered when biosimilar monoclonals enter the market, at the latest; Define procedures for usage and substitution;Note: 1 ) Substitution: refers to the practice of dispensing one medicine instead of another equivalent and interchangeablemedicine at the pharmacy level without consulting with the prescriber. 2) Automatic Substitution: refers to the practicewhereby a pharmacist is obliged to dispense one medicine instead of another equivalent and interchangeable medicine due tonational or local requirements without consulting with the prescriber.
  • 18. Question 6 - Uptake Measures Listed by Member StateSubstitution (2/2) There is a proposal of the law for implementing therapeutic reference groups; Automatic substitution when initiating treatment with a biological drug; (…), automatic substitution triggers price reductions ("step price"), and it is a very transparent and robust system with appropriate safety mechanism, i.e. doctor’s reservation. Various models are being considered: automatic substitution without limitations, substitution at start of treatment, but not later;
  • 19. Question 6 - Uptake Measures Listed by Member StateOthers Shorter deadline for deciding on the price and inclusion in the system of reimbursement (60 days); A robust regulatory framework is likely to be the best measure to foster uptake, doctors are likely to be somewhat slow in moving towards biosimilars; Increased role of clinicians as fund holders or service managers.
  • 20. EGA Conclusions (1/2)There is a need for clear and unbiasedinformation from independent sources,targeting doctors, on the scientificconcept of biosimilars, their approvalprocess and their safety and efficacy.
  • 21. EGA Conclusions (2/2)Member States should put in placeprescribing guidelines that incentivizephysicians to increase the prescriptionof biosimilars, in addition toreimbursement rules that create thecondition for the uptake of thebiosimilars market.